Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04005352 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

A Phase 3 study of Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
734
Enrollment target
20
Study locations

NCT04005352 is a Phase 3 study of Age-related Macular Degeneration that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 734 participants, below the 1,498-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04005352, a Phase 3 study of Age-related Macular Degeneration, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
734 participants
Enrollment target
20
Study locations

Study Summary

This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.

Conditions Studied

Age-related Macular Degeneration

Interventions

  • BIOLOGICAL Brolucizumab 6 mg
  • BIOLOGICAL Aflibercept 2 mg

Study Locations (20)

Florida

  • Novartis Investigative Site - Fort Lauderdale
  • Novartis Investigative Site - Fort Myers
  • Novartis Investigative Site - Orlando
  • Novartis Investigative Site - Pinellas Park
  • Novartis Investigative Site - Winter Haven

California

  • Novartis Investigative Site - Huntington Beach
  • Novartis Investigative Site - Loma Linda
  • Novartis Investigative Site - Riverside
  • Novartis Investigative Site - Santa Ana

Oregon

  • Novartis Investigative Site - Portland
  • Novartis Investigative Site - Springfield

Texas

  • Novartis Investigative Site - Austin
  • Novartis Investigative Site - Bellaire

Arizona

  • Novartis Investigative Site - Phoenix

Illinois

  • Novartis Investigative Site - Springfield

Indiana

  • Novartis Investigative Site - Indianapolis

Iowa

  • Novartis Investigative Site - West Des Moines

Trial Details

FieldValue
Enrollment Target 734 participants
Start Date 2019-09-25
Est. Completion 2022-09-09
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04005352

The ClinicalTrials.gov registry entry for NCT04005352 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 734 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,498-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (51% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Brolucizumab 6 mg is the first listed.

NCT04005352 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Oregon.

Frequently Asked Questions

What is clinical trial NCT04005352 about?

NCT04005352 is a clinical study titled "Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)". This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.

What is the current status of trial NCT04005352?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 734 participants. The study started on 2019-09-25. Estimated completion is 2022-09-09.

What conditions does trial NCT04005352 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration.

What interventions are being tested in trial NCT04005352?

The interventions under investigation include: Brolucizumab 6 mg (BIOLOGICAL), Aflibercept 2 mg (BIOLOGICAL).

Who is sponsoring clinical trial NCT04005352?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04005352 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Age-related Macular Degeneration

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.